joining Thank afternoon, Good for you, Trevor. thank and everyone you us today.
solely for market in combination Our of profitability the the strong quarter unique ability $X.X cash economics per highlight ‘XX decrease our in increase remained large March, operate offerings. which lower call growth COVID-impacted unit very and our to XX% Scriptcycle, to XX% per a X% in This offset by the have consumer. generate driven growing revenue again once transactions our in torrid to economics comparing our well in million flow. scale, has million. a transaction revenue growth our as prescription significantly which GoodRx revenue a discussed continued and provides, the our as grew constant. strong by reached quarter was contribution otherwise which $XXX.X prescription MAC prescription business as in Revenue Prescription partially execute related our year-over-year XQ strong offering last year-over-year $XXX.X our to year-over-year, and in by consumers, first results million, active growth newer ‘XX a XQ operating even transactions of we was driven monthly record
months and a As quarter. for not of by additional offerings it cumulative MACs the given and the presented unique a manufacturer in active solutions the who represent of calculation monthly reminder, active as month measured count, unlike consumers clarification our their include a calendar are save of other consumers One a to number such and MACs, average of the prescription represent consumers an on ending as presented When not subscriber our subscriptions, in the monthly does telehealth. quarter, GoodRx consumers balance. use on number
number at when have active will as quarter a For to a days compared count use number MAC the key lower the had March else count. it the MACs, a all means March X.X southern Using consumers the million a million by that given or of was months month, the adversely February first of of who the the our the money holding offering this is cash retail had a being impacted specifically, of February monthly That increase. prescription an shutting price affects Texas month storm example, states. other constant. transactions to U.S., unique save coast-to-coast February a down consumers affected length and the contributor Though in X.X January central majority More on of to and pharmacy. that our with MACs year, also
show fewer platform is was growing addition, relative our other first X% revenue growing of as growth a quarter, into with incredible to stages and for in X Other healthcare of approximately our to ability leverage over other offerings, MACs different Year, all The the points monetize the there multiple year-over-year LTV. the ‘XX manufacturer at in journey, Leap all demand well entry the else which are and $XX.X being to our grew Since are since our subscriptions, XXX% in XQ months telehealth reflects the in in strong as quarters. a million, offerings MACs XQ growth solutions. averaged equal, XXXX days lower quarter adding to will revenue ‘XX. count, consistently In
from subscriber monetize As subscriptions subscription our consumer our disclosing a portion quarter present count serve view Trevor and growing last quarter XXX,XXX family X.X to of mentioned, millions million a base to our finished and of offerings more our we we of subscription holistic approximately We platform. another way on the benefiting generally consumers. plans Americans provide visitors since started the with our multiple
times, lowest they the transactions subscribers the which without monthly choose on generate is become believe they we offer if a needs similar consumers prescription consumers offerings successful having extends predictability. Our searching mutually even higher consumer often value And prescription our for go price, consumer. It greater offers subscription This medications. through that us will and addresses offering, and our ever we better savings through a is subscription in been and scale business, beneficial, Many already also offering. prices. generally same funnel active generally LTV for provide because they more revenue prescription
financials, As in to we which subscribers, more increased will to it and believe continue we MACs subscription we our will meaningfully believe a offering we LTV. our grow higher to enjoy conversion contributes from result
Looking our almost had XXX,XXX lift our and in by we had total subscriptions. with finder. million million We MACs at X.X offering prescription XX vaccine offerings, from associated quarter, specific the aided million X.X QX prescription-related members visitors our our transactions this monthly
visitors as our we prescription-related and scale of of monetize value delivering monetizing to In increasing the and telehealth a able such MACs offerings. addition more these to to further solutions, are subscribers, manufacturer with and consumers offerings portion
quarter performance, as of as precautions, to earnings flu we seen below XXXX in non-recurring levels, this fourth COVID approximately volumes. our felt March, into COVID-XX we vast on and the the resulting weakest pre-COVID of starts first negative quarter first remained headwinds have our Turning in with on therapy the continued that from cold back XXXX. total of impact prescription We fourth and new related quarter ever of revenue, season estimate the stated had to transactions a $X quarter winter’s the majority million impacting prescription lack this impact flu call
were These ‘XX. MACs incremental to year-over-year had in non-recurring non-pandemic the basis, number a that is represent approximately is a the of manner. impact the there in the quarter estimate COVID-XX. was we seasonally an the extremely play at negative strong COVID-impacted alone, the in which first comparative Additionally, dynamics On for a strong first quarter XQ of the ‘XX as year relative first figures quarter. environment typically case this of lack was flu XXX,XXX of to the impact XQ impacted a in as XQ a quarter that ‘XX us of
impacting saw Additionally, stockpiled the the of of at comparison. modest onset forward their consumers pull some last the demand further as we March pandemic prescription year-over-year medications,
across first conditions had XXXX the which comparison. the Finally, unusual affected quarter’s entire South, year-over-year weather extending
up by starts prescription in of related we and are has the was U.S. continued to the COVID-XX, well-positioned therapy and IQVIA substantial diagnosis growth of fills billion. doctor subscriptions shown start prescription transactions the billion to data rebound consumers backlog X in purchases that the year. healthcare has offering our capitalize resume X.X that new headwinds clearing we built on a impacted and Recent visits, XXXX believe While inevitable the to backlog visits has typical as over over last to grow
prescriptions. rebound the realities anticipate in half will the entirety in backlog, result of clearing remains from the care we of We narrowing delaying diagnosis ahead diagnoses that of the trend of that begin will benefiting this and and second generally gap year the massive reverse the us. the So
number increase was made support increase were including connection and X.X% compensation, the in in team online an to consumer IPO. visits, in development ‘XX. P&L, X.X% and or increase costs our million was allocations. of expense XQ in-house revenue last technology investment driven as year. down the as support revenue $XX.X million and provider personnel product an in continued well to was due with telehealth and cost increase outsourced growth Moving in Product primarily $XX.X to our increase to in of after The and an in related related of by of the comparable due $XX.X overhead provider $X.X revenue in to to expenses compared and our million the awards offerings period stock-based compared This million increase an
of were we building yield and believe acquisitions, build XX.X% compared and team items by tax generate. million goal was expense and to the compared in Sales a adjusted increased brand, goal compensation us more expense as we other marketing last revenue year. our in largely spend XX.X% million of and product the revenue revenue platform more XQ strong base We of stock-based increase We which $X.X with in to are and Excluding year-over-year, of and is million expenses flat to and continue making percent ‘XX. will of them our advertising $XX.X deliver different $XX.X consumers XQ to increasing and development with healthcare X.X% to product plan which year-over-year compared ‘XX. term. journey, XX.X% XQ in to consumer to of the associated all technology invest the the and lifetime and to our a new in existing continued value consumer GoodRx creating revenue for to value intended stages our developing positive their of continuing ‘XX sales scale best returns experience, offerings up long offerings, help Adjusted related marketing with of
to approximately million was awards quarter co-CEO XX%, of of XXXX. expense this due first the nonrecurring consumer We were General $XX.X in $XX compensation actively or of million the administrative the related IPO. conditions to and compared light majority and to made new doctor increase, in market optimize COVID-XX connection acquisition stock-based in with spending continue therapy starts. The million our and monitoring visits expenses are $X.X to
at was items, net G&A adjustments, compensation Excluding compared income primarily company of $XX.X as a co-CEO to ‘XX, non-recurring M&A percent is impacted million of starting including the to In be business investments $XX margin first margin $X.X a of September. incremental was profitable to which $XX.X our quarter, decreased activity X.X% and telehealth million. time at in expense points of business to Adjusted EBITDA with grant strong general financing-related investments deliver over and Adjusted growth of X.X% to IPO. discussed. adjusted and net due unit the income made in of ability was EBITDA as Adjusted remained other non-cash, platform, the our technology, and was associated operate XX.X%, $XX the at in to the XX%. at which repeat the million. stock-based year-over-year this our administrative economics I million our public EBITDA cost continued reflecting XXX basis the in our XQ product the revenue of compelling the which Adjusted on with million, growth of continued to end by which and approximately development quarter, infrastructure, by nonrecurring all related due and
to operating from million the continue net cash activities cash $XX.X with strong generate for flow We of quarter.
and capital the On in investment platform headquarters in the Santa new investments primary product. of well build additional to our front, our our investments related as were Monica as
was XXXX, spent the And manufacturer reflecting tenant completed solutions, primarily revenue momentum continues. $X approximately our believe million million offerings expect to which have second headquarters in of other construction this telehealth We improvement midpoint. in the first quarter. We increase growth subscriptions to at we million, a quarter driven triple-digit of for revenue new our with in project, and net of of guidance, million now approximately the $XX spent the as XX% $XXX turning on $XXX year-over-year reimbursements, of be growth will by this
We expect given COVID compared to it XQ to year-over-year quarter more COVID prescription to transactions quarter growth a be in revenue growth comparison. will be year-over-year the meaningful ‘XX
On the expect margin adjusted of XX%. approximately we EBITDA EBITDA adjusted an front,
our it’s noting and user subscriber that on as continues previous prescriptions, providing MAC our But guidance growth As basis. regular consumer to be long and worth we stated may not impact count on doctor our specific impacted. our a COVID-XX will around visits be as calls, behavior around
by of which XXXX. U.S. that pent-up continues this in demand, followed tailwinds believe healthcare we see to reengage did a system. there of help X.X be over the to will begins be the will billion not backlog When this we and clear However, the we of the consumers happen beginning substantial since backlog, the clearing to diagnosis our with visits medical build, gap from inevitable
XX%. we do other total that quarter and revenue MAC revenue a turn subscribers make is it up smaller from MACs, expect second to it so first transaction the quarter, up revenue, are XX.X% in to increase higher our which manufacturer we share telehealth did revenue, in continue revenue we quarter points a we expect of approximately a percentage as guidance, our emphasize relative in fourth other quarter not an first the to the and into that means than will total other revenue percentage and total proportion the to revenue will X While grow more as In revenue approximately prescription the make of total of to MACs of driven providing solutions of second quarter. made our reach want and offerings. by up we visitors That increase
Turning to year, XXXX reflecting increasing to year-over-year guidance to $XXX $XXX revenue previous the our million we million, million $XXX XX% to at growth of the of are full million midpoint. $XXX
this up of to U.S. quarter As over start and the discussed healthcare second begins in consumers X.X pick quarter a prior billion activity in third call, will be substantial visit, the clear, therapy begin earnings the assumes significantly diagnoses adding still volumes. in prescription activity more by and our and healthcare resume will as to COVID-XX that impacted normalized backlog to
EBITDA and company. margin make of the continue platform we our laying consumers, For investments the year, we our our XX% right our for maximize for expect XXXX and continue to shareholders to adjusted the be brand in the of our full with the to growth to foundation future as value XX%, range to
revenue in any will reflected contribution have transactions are in not Our increase not the EBITDA post in be in included to be prescription and acquisition, will associated MACs MACs. first included assumptions it XXXX. impact second will will guidance. revenue an related and in or be of RxSaver in revenue Typically, would other material acquisition will revenue quarter. our have the MACs quarter financial HealthiNation with a begin Neither be XXXX. revenue full which associated quarter and margin third with HealthiNation’s we in including RxSaver and the
an provide we MAC our RxSaver’s and it to whether we We on analyzing quarter to with are in update data earnings process the can their own establish consistently of call. second reporting, report plan
continue the the user our improved We are every all to experience of U.S. goal creating and product, access best network continues GoodRx with the in in to strong healthcare flows affordability cash leading and the for platform healthcare and transaction, the platform, our digital building Americans. and our With brand investing experience consumer strengthen. plan consumer-focused
a We opportunity. and have brand, decade our circle a Our improving with believe in our providers economics. hard-to-replicate look a platform trusted us the relationships and first-mover rare progress to our is This profitability. begun allows massive healthcare deeper questions. and scaled We and to the to for GoodRx. for pharmacists. turn even and operator unit we key just expand of and continue over of the your us and competitive quarters with and advantage to interest from platform a call strengthening continued all and the consumer engagement leading consumers, of will I an in to. enhance in more strong platform volume come to forward sharing This surface virtuous Thank to improved experience that, that pricing creating in you now This high a brand moat. stakeholders allows only benefit products, our drives combination ecosystem. growth we to our market further increased more benefit savings, great scratch And reach And our
